relatlimab

1. 12:56
   x.com

   At #ESMO26: In a 5 year analysis of the phase 3 RELATIVITY-047 trial comparing relatlimab + nivolumab versus nivolumab alone in patients with advanced melanoma, statistically signi

1. 08:01
   x.com

   At #ESMO26: In an analysis of the phase 3 RELATIVITY-047 trial comparing relatlimab + nivolumab vs nivolumab alone in patients with melanoma, high baseline levels of LAG3hi CD8+ T
2. 08:01
   Nat MedPick

   Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial.

   A 5-year analysis of the phase 3 RELATIVITY-047 trial (NCT03470922) shows that relatlimab plus nivolumab improved PFS, OS, and MSS compared with nivolumab monotherapy in advanced melanoma.

1. 08:00
   nature.com

   Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial

   The 5-year analysis of the phase 3 RELATIVITY-047 trial showed statistically significant differences in progression-free survival, overall survival, and melanoma-specific survival between relatlimab plus nivolumab and nivolumab alone in advanced melanoma.

Heat now 19·Peak in the comparable set 24 (Oct 25 09:00)·Change over 24h in the comparable set -4%·Participants now 4

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.